-
Sector Analysis
NewHydrogen Transition Market Outlook and Trends, Deals, Contracts, Policies, Projects and Key Players, Q2 2024
Hydrogen Transition Market Report Overview The total active and pipeline capacity of low-carbon hydrogen projects is 204 mtpa as of March 2024, of which 92% comes from green plants and the remaining from blue plants. Many regions of the world with ample renewable resources are pursuing large-scale green hydrogen projects to capitalize on the falling cost of producing renewable energy. Furthermore, the pipeline of upcoming green projects represents 1,374 GW of electrolyzer capacity, while upcoming blue projects would incorporate over...
-
Analyst Opinions
NewNorth America Energy Transition by Key Sectors and Companies Driving Development
North America’s energy transition is continuing to gather pace, with a combination of technological development and favorable policy incentives driving substantial growth across renewables, hydrogen and CCUS sectors. Technologies such as electric vehicles and renewable fuels are also experiencing increasing adoption albeit at a slower rate. Despite the current dominance of natural gas within North America’s generation mix, a rapid build-out of solar PV and wind capacity will boost renewable generation so that it will contribute 55% of total generation...
-
Analyst Opinions
NewDecarbonizing Maritime and Aviation Overview by Key Energy Transition Technologies and Case Studies, 2024 Update
Decarbonizing Maritime and Aviation Market Report Overview The automotive sector experiences a strong growth in demand for electric vehicles. However, the aviation and maritime sectors have been slow to decarbonize. To incentivize emission reductions, both sectors have set bold net-zero targets. However, according to the IEA, the sectors remain disoriented. Demand for cost-competitive and energy-dense fuels has led aviation and maritime to represent two of the most difficult to abate sectors. Both sectors will likely need to engage with a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986368 in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986368 in Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986368 in Epilepsy Drug Details: BMS-986368 (CC-97489) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enasidenib Mesylate in Cytopenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enasidenib Mesylate in Cytopenia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enasidenib Mesylate in Cytopenia Drug Details: Enasidenib mesylate (CC-90007, AG-221, Idhifa) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Margetuximab in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Margetuximab in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Margetuximab in Epithelial Ovarian Cancer Drug Details: Margetuximab (Margenza) is a...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Lutetium Lu 177 Vipivotide Tetraxetan in Metastatic Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Vipivotide Tetraxetan in Metastatic Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium Lu 177 Vipivotide Tetraxetan in Metastatic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CC-98633 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CC-98633 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-98633 in Relapsed Multiple Myeloma Drug Details: CC-98633 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CC-98633 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CC-98633 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-98633 in Refractory Multiple Myeloma Drug Details: CC-98633 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cadonilimab in Rectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Rectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cadonilimab in Rectal Cancer Drug Details: Cardinalizumab (Ketanil) is a bi-specific...